RT @CEPIvaccines: 📢CEPI's Chikungunya vaccine development partner @valnevaSE has published positive Phase 3 trial results in @TheLancet, demonstrating the single-dose vaccine is safe & immunogenic. This is a major milestone on the road towards a licensed vaccine against this debilitating disease. https://t.co/nsaaif2X1l

🐦🔗: https://n.respublicae.eu/EU_HaDEA/status/1668609681630064640